RESUMEN
Systemic lupus erythematosus (SLE) is a chronic autoimmune disease characterized by a wide spectrum of autoantibodies, among which anti-ribosomal P (anti-P) antibodies are considered to be closely related to the neuropsychiatric SLE (NPSLE). Hydroxychloroquine (HCQ) has been proven to be effective against a variety of autoimmune diseases and is an essential drug for the treatment of SLE. In this study, we investigated the effects of anti-ribosomal P (anti-P) antibodies on neural cells and determined whether hydroxychloroquine (HCQ) influenced the anti-P antibodies-induced changes. The results showed that the binding of anti-P antibodies with mouse neuroblastoma- 2a (N2a) cells and rat primary neurons resulted in elevated intracellular calcium levels, inducing decreased cell viability and cell apoptosis. These inhibitory effects were alleviated by HCQ in a concentration-dependent manner by reducing the intracellular calcium levels and modulating the expression of apoptotic proteins. In summary, our study demonstrates that anti-P antibodies induce neural cell damage. HCQ could ease the damage effects and may play a neuroprotective role in NPSLE.
Asunto(s)
Anticuerpos Antinucleares/metabolismo , Anticuerpos Antinucleares/toxicidad , Supervivencia Celular/efectos de los fármacos , Hipocampo/metabolismo , Hidroxicloroquina/farmacología , Animales , Anticuerpos Antinucleares/inmunología , Línea Celular Tumoral , Supervivencia Celular/fisiología , Células Cultivadas , Inhibidores Enzimáticos/farmacología , Hipocampo/citología , Humanos , Lupus Eritematoso Sistémico/inmunología , Lupus Eritematoso Sistémico/metabolismo , Ratones , Conejos , RatasRESUMEN
Pathogens such as the Epstein Barr virus (EBV) have long been implicated in the etiology of systemic lupus erythematosus (SLE). The Epstein Barr virus nuclear antigen I (EBNA-1) has been shown to play a role in the development of anti-nuclear antibodies characteristic of SLE. One mechanism by which EBV may play a role in SLE is molecular mimicry. We previously generated two monoclonal antibodies (mAbs) to EBNA-1 and demonstrated that they cross-react with double-stranded DNA (dsDNA). In the present study, we demonstrate that these mAbs have pathogenic potential. We show that they can bind to isolated rat glomeruli and that binding can be greatly diminished by pretreatment of glomeruli with DNase I, suggesting that these mAbs bind dsDNA in the kidney. We also demonstrate that these antibodies can deposit in the kidney when injected into mice and can induce proteinuria and elicit histopathological alterations consistent with glomerulonephritis. Finally, we show that these antibodies can cross-react with laminin and collagen IV in the extracellular matrix suggesting that direct binding to the glomerular basement membrane or mesangial matrix may also contribute to the antibody deposition in the kidney. In summary, our results indicate that EBNA-1 can elicit antibodies that cross-react with dsDNA, that can deposit in the kidney, and induce kidney damage. These results are significant because they support the role of a viral protein in SLE and lupus nephritis.
Asunto(s)
Anticuerpos Antinucleares/toxicidad , Anticuerpos Monoclonales/toxicidad , Anticuerpos Antivirales/inmunología , ADN/inmunología , Infecciones por Virus de Epstein-Barr/inmunología , Antígenos Nucleares del Virus de Epstein-Barr/inmunología , Glomérulos Renales/inmunología , Animales , Anticuerpos Antinucleares/inmunología , Anticuerpos Monoclonales/genética , Anticuerpos Monoclonales/inmunología , Anticuerpos Monoclonales/aislamiento & purificación , Colágeno/inmunología , Reacciones Cruzadas/inmunología , Desoxirribonucleasa I , Infecciones por Virus de Epstein-Barr/metabolismo , Matriz Extracelular/genética , Matriz Extracelular/inmunología , Femenino , Membrana Basal Glomerular/inmunología , Membrana Basal Glomerular/metabolismo , Glomerulonefritis/inmunología , Glomerulonefritis/patología , Glomerulonefritis/virología , Células HEK293 , Humanos , Inmunoglobulina G/inmunología , Glomérulos Renales/patología , Laminina/inmunología , Ratones , Ratones Endogámicos BALB C , Imitación Molecular , Proteinuria/inmunología , Ratas , Ratas Sprague-DawleyRESUMEN
Systemic lupus erythematosus is an inflammatory autoimmune syndrome of unknown cause. Kidney disease is a central and serious complication in this syndrome. Deposition of chromatin-containing immune complexes within glomerular membranes is considered a key event in the pathogenesis of lupus nephritis. One set of autoantibodies that participate in these complexes is directed against components of chromatin, particularly against double-stranded DNA (dsDNA). Matzinger's danger model implicates chromatin fragments as both inducers and glomerular targets for nephritogenic anti-dsDNA and anti-nucleosome antibodies. In context of this model, apoptosis, secondary necrosis, and exposure of chromatin fragments may causally trigger autoimmunity and subsequent lupus nephritis. The exposure of glomerular basement membrane-associated extracellular chromatin depends on an observed acquired downregulation of renal DNase1 transcription and loss of nuclease activity preceding development of severe nephritis; this downregulation would result in reduced fragmentation and clearance of chromatin fragments. These fragments bind glomerular basement membrane structures with high affinity. In addition, exposed chromatin fragments contain structures that stimulate the innate immune system through Toll-like receptors and the adaptive immune system to produce affinity-maturated pathogenic anti-chromatin and anti-dsDNA antibodies that are central to the development of lupus nephritis.
Asunto(s)
Anticuerpos Antinucleares/toxicidad , Enfermedades Renales/inmunología , Lupus Eritematoso Sistémico/inmunología , Animales , Modelos Animales de Enfermedad , Humanos , Inflamación/inmunología , Enfermedades Renales/etiología , Glomérulos Renales/inmunología , Nefritis Lúpica/inmunología , Nefritis Lúpica/patología , Ratones , Ratones Endogámicos , Proteinuria/inmunologíaRESUMEN
OBJECTIVES: There is considerable evidence suggesting that anti-double-stranded deoxyribonucleic acid (anti-dsDNA) antibodies are involved in the pathogenesis of lupus nephritis. It was shown previously using severe combined immune deficient (SCID) mice that when the hybridomas secreting human immunoglobulin G (IgG) anti-dsDNA antibodies, RH14 and DIL-6, were implanted intraperitoneally the antibodies produced by RH14, but not DIL-6, deposited in the kidneys, caused pathological changes in the renal tissues and induced proteinuria. In this study we have further analysed the effect of activated terminal complement proteins and interleukin-10 (IL-10) in the pathogenesis of glomerulonephritis caused by the RH-14. METHODS: SCID mice implanted with RH-14 or DIL-6 cell lines were treated with neutralizing antibodies to IL-10 (mAb B-S10) or anti-complement factor 5 (anti-C5) (mAb BB5.1) intraperitoneally. Control groups received either an isotype control antibody (135.8) or phosphate-buffered saline (PBS). Serum human IgG levels and proteinuria were estimated and the extent of renal involvement was examined by histopathological and electron microscopic techniques. RESULTS: While there was a tendency to reduce proteinuria in the anti-IL-10 injected group the anti-C5 injected group showed a significant reduction in proteinuria (P<0.01) compared with the groups injected with either the control mAb or PBS. There was a considerable reduction in the serum human IgG levels in the anti-IL-10 but not in the anti-C5 treated animals. Both anti-IL-10 and anti-C5 treated groups showed significantly reduced renal impairment as revealed by histopathological examination and proteinuria assessment. CONCLUSION: The findings, while confirming the role of IL-10 and activated terminal complement component in the production of antibody at the cellular level and at the site of glomerular immune deposition in this model, respectively, also suggest the beneficial effect of a combined therapy using both anti-IL-10 and anti-C5 mAb to prevent or reduce the effect of the humoral immune response in lupus disease.
Asunto(s)
Anticuerpos Antinucleares/toxicidad , Enfermedades Autoinmunes/inmunología , Complemento C5/inmunología , Interleucina-10/inmunología , Nefritis Lúpica/inmunología , Animales , Anticuerpos Monoclonales/inmunología , Anticuerpos Monoclonales/uso terapéutico , Enfermedades Autoinmunes/patología , Enfermedades Autoinmunes/prevención & control , ADN/inmunología , Humanos , Inmunoglobulina G/sangre , Glomérulos Renales/ultraestructura , Nefritis Lúpica/patología , Nefritis Lúpica/prevención & control , Ratones , Ratones SCID , Microscopía Electrónica , Proteinuria/inmunología , Proteinuria/prevención & controlRESUMEN
OBJECTIVE: An animal model was used to investigate an autoimmune etiology for some cases of Tourette's syndrome. METHOD: Sera from 12 patients with Tourette's syndrome with high levels of antineural or antinuclear antibodies were infused bilaterally into the ventrolateral striatum of rats. Sera from 12 additional Tourette's syndrome patients and 12 normal subjects (both groups with low levels of autoantibodies) were infused for comparison. Rates of oral stereotypies were recorded by observers who were blind to the origin of the infused sera. RESULTS: Oral stereotypies significantly increased in the rats infused with sera from the patients with high levels of autoantibodies. CONCLUSIONS: The results are consistent with an autoimmune etiology in a subset of cases of Tourette's syndrome.
Asunto(s)
Anticuerpos Antinucleares/toxicidad , Autoanticuerpos/toxicidad , Cuerpo Estriado/inmunología , Modelos Animales de Enfermedad , Síndrome de Tourette/inmunología , Adolescente , Adulto , Animales , Anticuerpos Antinucleares/sangre , Autoanticuerpos/sangre , Mapeo Encefálico , Niño , Femenino , Humanos , Inyecciones , Masculino , Ratas , Ratas Sprague-Dawley , Conducta Estereotipada/efectos de los fármacos , Conducta Estereotipada/fisiologíaRESUMEN
Cytotoxicity of anti-DNA autoantibodies from sera of SLE and CLL patients was assayed on permanent cell lines L929, HL-60, Raji, and K562. L929 cells appeared to be the most sensitive to antibody treatment. DNA-hydrolyzing properties of the same autoantibody preparations were analyzed in parallel. The data obtained outlined the correlation between cytotoxicity and DNA-hydrolyzing properties of these autoantibodies. It was shown that treatment of the cells with cytotoxic anti-DNA autoantibodies induced internucleosomal DNA fragmentation and Annexin V binding to the cell surface characteristic of apoptotic pathway of cell death. A time-dependent profile of antibody-mediated toxicity to L929 cells suggested recruitment of at least two distinct mechanisms of cell death. The first peak of cell death observed in 3 h of incubation was completely inhibited by preincubation of cells with caspase inhibitor YVAD-CHO, while the second increase in cell mortality (18-30 h) persisted. Possible mechanisms for anti-DNA autoantibody cytotoxicity are discussed.
Asunto(s)
Anticuerpos Antinucleares/inmunología , Anticuerpos Antinucleares/toxicidad , ADN/inmunología , Leucemia Linfocítica Crónica de Células B/inmunología , Lupus Eritematoso Sistémico/inmunología , Inhibidores de Caspasas , Caspasas/metabolismo , Muerte Celular/efectos de los fármacos , ADN/metabolismo , Fragmentación del ADN/efectos de los fármacos , Citometría de Flujo , Humanos , Hidrólisis/efectos de los fármacos , Sueros Inmunes/inmunología , Sueros Inmunes/toxicidad , Fragmentos Fab de Inmunoglobulinas/inmunología , Fragmentos Fab de Inmunoglobulinas/toxicidad , Leucemia Linfocítica Crónica de Células B/genética , Lupus Eritematoso Sistémico/genética , Factores de Tiempo , Células Tumorales CultivadasAsunto(s)
Anticuerpos Antinucleares/metabolismo , Anticuerpos Catalíticos/metabolismo , Animales , Anticuerpos Antinucleares/toxicidad , Anticuerpos Catalíticos/toxicidad , Enfermedades Autoinmunes/inmunología , Catálisis , Muerte Celular/efectos de los fármacos , Núcleo Celular/inmunología , ADN/inmunología , ADN/metabolismo , Humanos , Hidrólisis , Trastornos Linfoproliferativos/inmunología , RatonesRESUMEN
OBJECTIVE: The objective of this study was to assess the beneficial effects of an early administration of low dose linomide, a new immunomodulator, in an animal model of experimental systemic lupus erythematosus (SLE). METHODS: Experimental SLE was induced in naive BALB/c mice, by immunization with anti-DNA mAb (MIV-7). Control Mice immunized with irrelevant human IgM served as controls. The immunized mice were treated with linomide (0.1 mg/ml in the drinking water), four weeks prior to the first immunization, at an early stage of the disease induction (one month after boost injection), or at a later stage (3 months following boost immunization). The treatment duration was 3 months in all schedules. The follow-up studies continued for 8 weeks after discontinuation of the treatment. The presence in the serum of autoantibodies against ssDNA, dsDNA histones, phospholipids and an irrelevant autoantigen-pyruvate dehydrogenase, was determined by enzyme-linked immunosorbent assay (ELISA). The clinical parameters assessed included erythrocyte sedimentation rate, peripheral blood cell counts and proteinuria. RESULTS: There was a 50-64% decrease in autoantibody levels in the sera of mice immunized with anti-DNA (MIV-7) mAb at the early stage of experimental SLE in mice which received linomide for a period of 3 months. No effect of linomide was noted in mice which received the drug during the later stages of experimental SLE when the disease was fully developed. Linomide had a preventive effect on the induction of experimental SLE in naive mice, when the treatment was initiated before the induction of the disease. This effect was abolished following cessation of the treatment. CONCLUSIONS: Linomide proved to be effective at the early stages of induction of the experimental SLE. However, the autoantibody levels rose following discontinuation of the therapy.
Asunto(s)
Adyuvantes Inmunológicos/uso terapéutico , Enfermedades Autoinmunes/terapia , Hidroxiquinolinas/uso terapéutico , Lupus Eritematoso Sistémico/terapia , Animales , Anticuerpos Antinucleares/toxicidad , Anticuerpos Monoclonales/toxicidad , Enfermedades Autoinmunes/etiología , Modelos Animales de Enfermedad , Evaluación Preclínica de Medicamentos , Humanos , Inmunización Pasiva , Lupus Eritematoso Sistémico/etiología , Ratones , Ratones Endogámicos BALB CRESUMEN
It has previously been shown that immunization with pathogenic anti-DNA idiotypes (Ids; e.g. 16/6 Id) leads to the induction of experimental system lupus erythematosus (SLF) in naive mice. The disease is characterized by serological (e.g. anti-double-strand DNA), clinical (elevation of erythrocyte sedimentation rate, leukopenia and proteinuria) and histological (immune complex deposition in kidneys) parameters. To determine whether the 16/6 Id carrying anti-DNA antibodies has unique pathogenic ability, in the current study we have employed diverse sources of anti-DNA antibodies to induce experimental SLE. An IgM anti-DNA antibody lacking the 16/6 Id was able to induce the production of the serological markers of experimental SLE, but not the clinico-histological findings. Furthermore, an IgA anti-DNA (16/6 Id derived from the serum of a patient with celiac disease was very effective in inducing the whole presentation of experimental SLE. Other anti-DNA antibodies failed to induce the autoimmune condition. Combined with our previous experience, the current study points to the diverse potential of various anti-DNA antibodies to induce SLE. The 16/6 Id is only one of a list of the potent pathogenic anti-DNA Ids. These facts may explain in part the diversity of clinical presentations of SLE, including asymptomatic subjects who carry high serum titers of anti-DNA antibodies.
Asunto(s)
Anticuerpos Antinucleares/inmunología , Anticuerpos Antinucleares/toxicidad , ADN/inmunología , Lupus Eritematoso Sistémico/inducido químicamente , Animales , Anticuerpos Antinucleares/clasificación , Ratones , Ratones Endogámicos BALB CRESUMEN
Gaucher's disease (GD) is associated with hyperactivity of the immune system, which manifests by polyclonal hypergamma-globulinemia and an increased incidence of monoclonal gammopathies in GD patients. We analyzed sera of 43 patients with GD for the presence of autoantibodies against 14 autoantigens. The results demonstrated a significant increase in the incidence of all autoantibodies tested, ranging from 11% for anti-RNP, pyruvate dehydrogenase (PDH), and DNA antibodies to 57% for rheumatoid factor. The autoantibodies were of all three isotypes, namely, IgG, IgM, and IgA. There was no correlation between the levels of immunoglobulins in the serum and the titer of autoantibodies found. Immunization of naive mice with a pool of purified anti-DNA antibodies form GD patients did not result in induction of experimental systemic lupus erythematosus (SLE), suggesting that they may represent natural autoantibodies that are not pathogenic. In conclusion, we found high titers of natural, polyspecific, nonpathogenic autoantibodies in the sera of GD patients.
Asunto(s)
Autoanticuerpos/sangre , Enfermedad de Gaucher/inmunología , Adolescente , Adulto , Animales , Anticuerpos Antinucleares/toxicidad , Especificidad de Anticuerpos , Autoanticuerpos/biosíntesis , Autoanticuerpos/clasificación , Enfermedades Autoinmunes/etiología , Niño , Preescolar , Femenino , Enfermedad de Gaucher/sangre , Humanos , Inmunidad Innata , Isotipos de Inmunoglobulinas/sangre , Inmunoglobulinas/biosíntesis , Inmunoglobulinas/sangre , Masculino , Ratones , Ratones Endogámicos BALB C , Persona de Mediana EdadRESUMEN
Antibodies to DNA (anti-DNA) occur prominently in systemic lupus erythematosus and provoke inflammatory damage in the kidneys. To determine the factors that confer pathogenicity on antibodies of this specificity, we investigated the in vitro and in vivo glomerular binding by members of four clonally related sets of monoclonal anti-DNA antibodies from lupus mice. Somatic mutations within the clonal sets enhanced binding to double-stranded DNA (dsDNA). Binding to permeabilized glomeruli in vitro was observed among affinity-purified preparations of these antibodies independent of specificity for dsDNA. In normal mice injected with hybridoma cell lines, nephritis as assessed by histology and immunofluorescence did not correlate with antibody affinity for DNA. By multivariate analysis, in vitro glomerular binding was the most predictive parameter of histologic outcome. These findings indicate that somatic mutations occurring during maturation of the autoimmune response do not necessarily enhance pathogenicity.
Asunto(s)
Anticuerpos Antinucleares/toxicidad , Especificidad de Anticuerpos , ADN/inmunología , Región Variable de Inmunoglobulina/genética , Nefritis Lúpica/inmunología , Mutación , Secuencia de Aminoácidos , Animales , Anticuerpos Antinucleares/genética , Anticuerpos Monoclonales , Femenino , Hibridomas , Glomérulos Renales/inmunología , Glomérulos Renales/patología , Nefritis Lúpica/etiología , Ratones , Ratones Endogámicos BALB C , Ratones Endogámicos DBA , Ratones Mutantes , Datos de Secuencia Molecular , Homología de Secuencia de AminoácidoRESUMEN
Systemic lupus erythematosus (SLE) can be induced in mice by immunization with a human anti-DNA IgM mAb that was derived from a patient with cold agglutinin disease. The latter anti-DNA mAb expresses the common idiotype (Id) designated 16/6 Id. The original human hybridoma 16/6 that secreted an IgM antibody that bound ssDNA and carried the 16/6 Id had switched in culture to secrete an IgG molecule. Herein we show that the IgG 16/6 antibody contains the previously reported characteristics of the original IgM 16/6 mAb: it expresses the 16/6 Id and is capable of inducing experimental SLE in susceptible mouse strains. The identify of the IgG 16/6 anti-DNA mAb to the original IgM mAb was shown both by serological techniques and at the T cell level. The human IgG 16/6 mAb was found to be encoded by a germline gene from the human VH4 gene family, with high similarity to the germline gene VH4.21 that was previously shown to code for anti-DNA antibodies isolated from SLE patients. The VH4.21 germline gene was found to also code for most antibodies with cold agglutinin activity that were isolated from patients with cold agglutinin disease.
Asunto(s)
Anticuerpos Antinucleares/genética , Anticuerpos Monoclonales/genética , Cadenas Pesadas de Inmunoglobulina/genética , Región Variable de Inmunoglobulina/genética , Lupus Eritematoso Sistémico/inmunología , Secuencia de Aminoácidos , Animales , Anticuerpos Antinucleares/administración & dosificación , Anticuerpos Antinucleares/toxicidad , Anticuerpos Monoclonales/administración & dosificación , Anticuerpos Monoclonales/toxicidad , Secuencia de Bases , Femenino , Humanos , Lupus Eritematoso Sistémico/etiología , Ratones , Ratones Endogámicos BALB C , Datos de Secuencia MolecularRESUMEN
We have used site-directed mutagenesis to change amino acid residues in the heavy chain of the pathogenic R4A anti-double-stranded DNA (dsDNA) antibody and have looked for resultant alterations in DNA binding and in pathogenicity. The data demonstrate that single amino acid substitutions in both complementarity determining and framework regions alter antigen binding. Changes in only a few amino acids entirely ablate DNA specificity or cause a 10-fold increase in relative binding. In vivo studies in mice of the pathogenicity of the mutated antibodies show that a single amino acid substitution leading to a loss of dsDNA binding leads also to a loss of glomerular sequestration. Amino acid substitutions that increase relative affinity for dsDNA cause a change in localization of immunoglobulin deposition from glomeruli to renal tubules. These studies demonstrate that small numbers of amino acid substitutions can dramatically alter antigen binding and pathogenicity, and that the pathogenicity of anti-DNA antibodies does not strictly correlate with affinity for DNA.
Asunto(s)
Anticuerpos Antinucleares/inmunología , Análisis Mutacional de ADN , ADN/inmunología , Secuencia de Aminoácidos , Animales , Anticuerpos Antinucleares/toxicidad , Ensayo de Inmunoadsorción Enzimática , Ratones , Ratones Endogámicos BALB C , Datos de Secuencia Molecular , Mutagénesis Sitio-Dirigida , Relación Estructura-ActividadRESUMEN
Neonatal lupus erythematosus (NLE) syndrome is a result of the transfer of autoantibodies produced by the mother, across the placenta, to the fetus. NLE is characterized by a transient dermatitis, a variety of systemic and hematological abnormalities, and isolated cases of congenital heart block. The latter has been reported to be due to the presence of autoantibodies specific to La (SS-B) and/or Ro (SS-A). As female mice with experimental SLE, induced by immunization with the monoclonal anti-DNA 16/6 Id, produce a variety of autoantibodies including anti-Ro and anti-La antibodies, we examined the relevance of NLE in the murine system. Offspring of SLE-afflicted BALB/c mothers possessed antibody titers to the 16/6 Id, ssDNA, and nuclear extract, which gradually declined until reduced to normal levels by day 60 after delivery. Antibody titers in the sera of the mothers remained elevated throughout this period. Electrocardiograms were recorded from groups of neonates from mothers with experimental SLE. The results indicated that a high percentage of the offspring had defects in their conduction system including first, second, and third degree heart block; significant bradycardia; and wide QRS complex. Normal patterns were observed in offspring of healthy mothers. Experiments done with mice that were exposed to SLE-related autoantibodies early in their development indicated that offspring to mothers with experimental SLE were neither protected nor more susceptible to disease induction by the 16/6 Id.
Asunto(s)
Animales Recién Nacidos/inmunología , Enfermedades Autoinmunes/inmunología , Modelos Animales de Enfermedad , Inmunidad Materno-Adquirida , Lupus Eritematoso Sistémico/congénito , Complicaciones del Embarazo/inmunología , Animales , Anticuerpos Antinucleares/inmunología , Anticuerpos Antinucleares/toxicidad , Anticuerpos Monoclonales/inmunología , Anticuerpos Monoclonales/toxicidad , Autoanticuerpos/análisis , Bradicardia/congénito , Bradicardia/etiología , Femenino , Bloqueo Cardíaco/congénito , Bloqueo Cardíaco/epidemiología , Bloqueo Cardíaco/etiología , Humanos , Inmunización , Incidencia , Lupus Eritematoso Sistémico/inmunología , Masculino , Intercambio Materno-Fetal , Ratones , Ratones Endogámicos BALB C/inmunología , EmbarazoRESUMEN
Experimental systemic lupus erythematosus (SLE) in mice can be induced by immunization either with a human monoclonal anti-DNA antibody bearing the 16/6 idiotype (16/6 Id) or with a mouse monoclonal anti-idiotypic antibody specific for the 16/6 Id. In the present report we investigated the pathogenic role of a monoclonal anti-La autoantibody in the induction and mediation of experimental SLE in mice. The monoclonal anti-La antibody was derived from a mouse in which experimental SLE was induced by immunization with the monoclonal anti-16/6 Id antibody. Following immunization with the anti-La antibody the mice produced antibodies to double-stranded DNA, single-stranded DNA, Sm, SS-A/Ro, SS-B/La, and ribonucleoprotein. Furthermore, even though the anti-La antibody does not express nor react with the 16/6 Id, the immunized mice produced high titers of anti-16/6 Id antibodies as well as 16/6 Id bearing antibodies. Four months following immunization the mice exhibited significant proteinuria, and kidney sections revealed immune complex deposits on the basement membrane of the glomeruli. These results suggest that anti-La autoantibodies are involved in the induction and mediation of SLE in mice.